866-997-4948(US-Canada Toll Free)

Prostate Cancer - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 1845 Pages

Prostate Cancer - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prostate Cancer - Pipeline Review, H1 2017, provides an overview of the Prostate Cancer (Oncology) pipeline landscape.

Prostate cancer is a form of cancer that affects men and starts off in the prostate gland. Prostate cancer usually occurs in older men. Symptoms include trouble urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips or thighs, bone pain and erectile dysfunction. Predisposing factors include age, family history and obesity. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prostate Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Prostate Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prostate Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 18, 98, 108, 6, 247, 35 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 15, 58 and 20 molecules, respectively.

Prostate Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Prostate Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Prostate Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Prostate Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Prostate Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Prostate Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Prostate Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Prostate Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 13
Prostate Cancer - Overview 14
Prostate Cancer - Therapeutics Development 15
Prostate Cancer - Therapeutics Assessment 78
Prostate Cancer - Companies Involved in Therapeutics Development 113
Prostate Cancer - Drug Profiles 263
Prostate Cancer - Dormant Projects 1732
Prostate Cancer - Discontinued Products 1763
Prostate Cancer - Product Development Milestones 1774
Appendix 1784

List of Tables
Number of Products under Development for Prostate Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..15), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..16), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..17), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..18), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Companies, H1 2017 (Contd..4), H1 2017
Products under Development by Companies, H1 2017 (Contd..5), H1 2017
Products under Development by Companies, H1 2017 (Contd..6), H1 2017
Products under Development by Companies, H1 2017 (Contd..7), H1 2017
Products under Development by Companies, H1 2017 (Contd..8), H1 2017
Products under Development by Companies, H1 2017 (Contd..9), H1 2017
Products under Development by Companies, H1 2017 (Contd..10), H1 2017
Products under Development by Companies, H1 2017 (Contd..11), H1 2017
Products under Development by Companies, H1 2017 (Contd..12), H1 2017
Products under Development by Companies, H1 2017 (Contd..13), H1 2017
Products under Development by Companies, H1 2017 (Contd..14), H1 2017
Products under Development by Companies, H1 2017 (Contd..15), H1 2017
Products under Development by Companies, H1 2017 (Contd..16), H1 2017
Products under Development by Companies, H1 2017 (Contd..17), H1 2017
Products under Development by Companies, H1 2017 (Contd..18), H1 2017
Products under Development by Companies, H1 2017 (Contd..19), H1 2017
Products under Development by Companies, H1 2017 (Contd..20), H1 2017
Products under Development by Companies, H1 2017 (Contd..21), H1 2017
Products under Development by Companies, H1 2017 (Contd..22), H1 2017
Products under Development by Companies, H1 2017 (Contd..23), H1 2017
Products under Development by Companies, H1 2017 (Contd..24), H1 2017
Products under Development by Companies, H1 2017 (Contd..25), H1 2017
Products under Development by Companies, H1 2017 (Contd..26), H1 2017
Products under Development by Companies, H1 2017 (Contd..27), H1 2017
Products under Development by Companies, H1 2017 (Contd..28), H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..10), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..11), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..12), H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..13), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..12), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Number of Products by Stage and Molecule Type, H1 2017 (Contd..1), H1 2017
Prostate Cancer - Pipeline by 3-V Biosciences Inc, H1 2017
Prostate Cancer - Pipeline by 4SC AG, H1 2017
Prostate Cancer - Pipeline by AB Science SA, H1 2017
Prostate Cancer - Pipeline by AbbVie Inc, H1 2017
Prostate Cancer - Pipeline by Actinium Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by ADC Therapeutics Sarl, H1 2017
Prostate Cancer - Pipeline by Addex Therapeutics Ltd, H1 2017
Prostate Cancer - Pipeline by Aduro BioTech Inc, H1 2017
Prostate Cancer - Pipeline by Advanced Accelerator Applications SA, H1 2017
Prostate Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2017
Prostate Cancer - Pipeline by Advantagene Inc, H1 2017
Prostate Cancer - Pipeline by Advaxis Inc, H1 2017
Prostate Cancer - Pipeline by Aeglea BioTherapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Aeolus Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Aeterna Zentaris Inc, H1 2017
Prostate Cancer - Pipeline by Akshaya Bio Inc, H1 2017
Prostate Cancer - Pipeline by Alchemia Ltd, H1 2017
Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Alissa Pharma, H1 2017
Prostate Cancer - Pipeline by Almac Discovery Ltd, H1 2017
Prostate Cancer - Pipeline by Ambrx Inc, H1 2017
Prostate Cancer - Pipeline by Amgen Inc, H1 2017
Prostate Cancer - Pipeline by Anavex Life Sciences Corp, H1 2017
Prostate Cancer - Pipeline by AndroScience Corp, H1 2017
Prostate Cancer - Pipeline by AnGes MG Inc, H1 2017
Prostate Cancer - Pipeline by AntiCancer Inc, H1 2017
Prostate Cancer - Pipeline by Antigen Express Inc, H1 2017
Prostate Cancer - Pipeline by Antisense Therapeutics Ltd, H1 2017
Prostate Cancer - Pipeline by Apcure SAS, H1 2017
Prostate Cancer - Pipeline by Aphios Corp, H1 2017
Prostate Cancer - Pipeline by APIM Therapeutics AS, H1 2017
Prostate Cancer - Pipeline by Aptevo Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Aptose Biosciences Inc, H1 2017
Prostate Cancer - Pipeline by ARMO Biosciences Inc, H1 2017
Prostate Cancer - Pipeline by Armour Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Arno Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by ArQule Inc, H1 2017
Prostate Cancer - Pipeline by Arrien Pharmaceuticals LLC, H1 2017
Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Arvinas Inc, H1 2017
Prostate Cancer - Pipeline by Asana BioSciences LLC, H1 2017
Prostate Cancer - Pipeline by Asieris Pharmaceuticals Co Ltd, H1 2017
Prostate Cancer - Pipeline by Astellas Pharma Inc, H1 2017
Prostate Cancer - Pipeline by AstraZeneca Plc, H1 2017
Prostate Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
Prostate Cancer - Pipeline by Avipep Pty Ltd, H1 2017
Prostate Cancer - Pipeline by Bavarian Nordic A/S, H1 2017
Prostate Cancer - Pipeline by Bayer AG, H1 2017
Prostate Cancer - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
Prostate Cancer - Pipeline by Bexion Pharmaceuticals LLC, H1 2017
Prostate Cancer - Pipeline by BHR Pharma LLC, H1 2017
Prostate Cancer - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017
Prostate Cancer - Pipeline by Biotest AG, H1 2017
Prostate Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Blirt SA, H1 2017
Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017
Prostate Cancer - Pipeline by Bukwang Pharm Co Ltd, H1 2017
Prostate Cancer - Pipeline by Camurus AB, H1 2017
Prostate Cancer - Pipeline by Can-Fite BioPharma Ltd, H1 2017
Prostate Cancer - Pipeline by CanBas Co Ltd, H1 2017
Prostate Cancer - Pipeline by Cantex Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by CEL-SCI Corp, H1 2017
Prostate Cancer - Pipeline by Celgene Corp, H1 2017
Prostate Cancer - Pipeline by CellCentric Ltd, H1 2017
Prostate Cancer - Pipeline by Celldex Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Cellectar Biosciences Inc, H1 2017
Prostate Cancer - Pipeline by Cellmid Ltd, H1 2017
Prostate Cancer - Pipeline by Cellular Biomedicine Group Inc, H1 2017
Prostate Cancer - Pipeline by Celprogen Inc, H1 2017
Prostate Cancer - Pipeline by Chamaeleo Pharma NV, H1 2017
Prostate Cancer - Pipeline by Clovis Oncology Inc, H1 2017
Prostate Cancer - Pipeline by CohBar Inc, H1 2017
Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H1 2017
Prostate Cancer - Pipeline by Corcept Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Corvus Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Crescendo Biologics Ltd, H1 2017
Prostate Cancer - Pipeline by Curadis GmbH, H1 2017
Prostate Cancer - Pipeline by CytomX Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Cytori Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by CytoVac A/S, H1 2017
Prostate Cancer - Pipeline by CZ BioMed Corp, H1 2017
Prostate Cancer - Pipeline by Daewoong Co Ltd, H1 2017
Prostate Cancer - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
Prostate Cancer - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
Prostate Cancer - Pipeline by DEKK-TEC Inc, H1 2017
Prostate Cancer - Pipeline by DexTech Medical AB, H1 2017
Prostate Cancer - Pipeline by Diffusion Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by DNJ Pharma Inc, H1 2017
Prostate Cancer - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017
Prostate Cancer - Pipeline by Eisai Co Ltd, H1 2017
Prostate Cancer - Pipeline by Eli Lilly and Company, H1 2017
Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H1 2017
Prostate Cancer - Pipeline by EndoCeutics Inc, H1 2017
Prostate Cancer - Pipeline by Endocyte Inc, H1 2017
Prostate Cancer - Pipeline by EntreChem SL, H1 2017
Prostate Cancer - Pipeline by EOS Biosciences Inc, H1 2017
Prostate Cancer - Pipeline by Errant Gene Therapeutics LLC, H1 2017
Prostate Cancer - Pipeline by Esperance Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by ESSA Pharma Inc, H1 2017
Prostate Cancer - Pipeline by Eureka Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Evgen Pharma Plc, H1 2017
Prostate Cancer - Pipeline by Exonate Ltd, H1 2017
Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Prostate Cancer - Pipeline by Ferring International Center SA, H1 2017
Prostate Cancer - Pipeline by Foresee Pharmaceuticals LLC, H1 2017
Prostate Cancer - Pipeline by Fountain Biopharma Inc, H1 2017
Prostate Cancer - Pipeline by Fujifilm Corp, H1 2017
Prostate Cancer - Pipeline by G1 Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Galectin Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Genelux Corp, H1 2017
Prostate Cancer - Pipeline by Genentech Inc, H1 2017
Prostate Cancer - Pipeline by GeneSegues Inc, H1 2017
Prostate Cancer - Pipeline by Genmab A/S, H1 2017
Prostate Cancer - Pipeline by Gilead Sciences Inc, H1 2017
Prostate Cancer - Pipeline by Glactone Pharma AB, H1 2017
Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H1 2017
Prostate Cancer - Pipeline by GlycoMimetics Inc, H1 2017
Prostate Cancer - Pipeline by GP Pharm SA, H1 2017
Prostate Cancer - Pipeline by GTx Inc, H1 2017
Prostate Cancer - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017
Prostate Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
Prostate Cancer - Pipeline by Health Ever Bio-Tech Co Ltd, H1 2017
Prostate Cancer - Pipeline by HitGen LTD, H1 2017
Prostate Cancer - Pipeline by Hybrigenics SA, H1 2017
Prostate Cancer - Pipeline by IC-MedTech Inc, H1 2017
Prostate Cancer - Pipeline by Ideaya Biosciences Inc, H1 2017
Prostate Cancer - Pipeline by IGF Oncology LLC, H1 2017
Prostate Cancer - Pipeline by Ignyta Inc, H1 2017
Prostate Cancer - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017
Prostate Cancer - Pipeline by Immune Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Immuneed AB, H1 2017
Prostate Cancer - Pipeline by Immunocore Ltd, H1 2017
Prostate Cancer - Pipeline by ImmunoFrontier Inc, H1 2017
Prostate Cancer - Pipeline by Immunomedics Inc, H1 2017
Prostate Cancer - Pipeline by Immupharma Plc, H1 2017
Prostate Cancer - Pipeline by IMPACT Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Incanthera Ltd, H1 2017
Prostate Cancer - Pipeline by Inflection Biosciences Ltd, H1 2017
Prostate Cancer - Pipeline by InKemia IUCT Group SA, H1 2017
Prostate Cancer - Pipeline by Innate Immunotherapeutics Ltd, H1 2017
Prostate Cancer - Pipeline by Innovation Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Inspyr Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Intech Biopharm Ltd, H1 2017
Prostate Cancer - Pipeline by Io Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
Prostate Cancer - Pipeline by Johnson & Johnson, H1 2017
Prostate Cancer - Pipeline by Jyant Technologies Inc, H1 2017
Prostate Cancer - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Kite Pharma Inc, H1 2017
Prostate Cancer - Pipeline by Komipharm International Co Ltd, H1 2017
Prostate Cancer - Pipeline by Konruns Pharmaceutical Co Ltd, H1 2017
Prostate Cancer - Pipeline by Kura Oncology Inc, H1 2017
Prostate Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017
Prostate Cancer - Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Lidds AB, H1 2017
Prostate Cancer - Pipeline by Luye Pharma Group Ltd, H1 2017
Prostate Cancer - Pipeline by MacroGenics Inc, H1 2017
Prostate Cancer - Pipeline by Mallinckrodt Plc, H1 2017
Prostate Cancer - Pipeline by Mateon Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by MaxiVAX SA, H1 2017
Prostate Cancer - Pipeline by Meabco A/S, H1 2017
Prostate Cancer - Pipeline by Med Discovery SA, H1 2017
Prostate Cancer - Pipeline by MediaPharma Srl, H1 2017
Prostate Cancer - Pipeline by MediGene AG, H1 2017
Prostate Cancer - Pipeline by MedImmune LLC, H1 2017
Prostate Cancer - Pipeline by Mediolanum farmaceutici SpA, H1 2017
Prostate Cancer - Pipeline by MEI Pharma Inc, H1 2017
Prostate Cancer - Pipeline by Merck & Co Inc, H1 2017
Prostate Cancer - Pipeline by Merck KGaA, H1 2017
Prostate Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Microlin Bio Inc, H1 2017
Prostate Cancer - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Minerva Biotechnologies Corp, H1 2017
Prostate Cancer - Pipeline by Mirati Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Mithra Pharmaceuticals SA, H1 2017
Prostate Cancer - Pipeline by MolMed SpA, H1 2017
Prostate Cancer - Pipeline by Monopar Therapeutics LLC, H1 2017
Prostate Cancer - Pipeline by Morphotek Inc, H1 2017
Prostate Cancer - Pipeline by MTG Biotherapeutics Inc, H1 2017
Prostate Cancer - Pipeline by NewLink Genetics Corp, H1 2017
Prostate Cancer - Pipeline by NormOxys Inc, H1 2017
Prostate Cancer - Pipeline by Novartis AG, H1 2017
Prostate Cancer - Pipeline by Novogen Ltd, H1 2017
Prostate Cancer - Pipeline by Novus Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Noxopharm Ltd, H1 2017
Prostate Cancer - Pipeline by Nymox Pharmaceutical Corp, H1 2017
Prostate Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2017
Prostate Cancer - Pipeline by Omeros Corp, H1 2017
Prostate Cancer - Pipeline by Omnitura Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by OncBioMune Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Oncodrone BV, H1 2017
Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by OncoMax, H1 2017
Prostate Cancer - Pipeline by OncoNOx ApS, H1 2017
Prostate Cancer - Pipeline by OncoTartis Inc, H1 2017
Prostate Cancer - Pipeline by OncoTherapy Science Inc, H1 2017
Prostate Cancer - Pipeline by Oncovir Inc, H1 2017
Prostate Cancer - Pipeline by Oncternal Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Oneness Biotech Co Ltd, H1 2017
Prostate Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017
Prostate Cancer - Pipeline by ORCA Therapeutics BV, H1 2017
Prostate Cancer - Pipeline by Oribase Pharma, H1 2017
Prostate Cancer - Pipeline by Oric Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Orion Oyj, H1 2017
Prostate Cancer - Pipeline by Orphagen Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Oxford BioMedica Plc, H1 2017
Prostate Cancer - Pipeline by Panacea Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Patrys Ltd, H1 2017
Prostate Cancer - Pipeline by PDS Biotechnology Corp, H1 2017
Prostate Cancer - Pipeline by Peptron Inc, H1 2017
Prostate Cancer - Pipeline by PepVax Inc, H1 2017
Prostate Cancer - Pipeline by Pfizer Inc, H1 2017
Prostate Cancer - Pipeline by Pharmedartis GmbH, H1 2017
Prostate Cancer - Pipeline by Pharmicell Co Ltd, H1 2017
Prostate Cancer - Pipeline by Pharminox Ltd, H1 2017
Prostate Cancer - Pipeline by Philogen SpA, H1 2017
Prostate Cancer - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Polyplus-Transfection SA, H1 2017
Prostate Cancer - Pipeline by Prima BioMed Ltd, H1 2017
Prostate Cancer - Pipeline by Progenics Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Provenance Biopharmaceuticals Corp, H1 2017
Prostate Cancer - Pipeline by PSites Pharma GmbH, H1 2017
Prostate Cancer - Pipeline by Quintessence Biosciences Inc, H1 2017
Prostate Cancer - Pipeline by Radiomedix Inc, H1 2017
Prostate Cancer - Pipeline by RedHill Biopharma Ltd, H1 2017
Prostate Cancer - Pipeline by Regulaxis SAS, H1 2017
Prostate Cancer - Pipeline by RhoVac AB, H1 2017
Prostate Cancer - Pipeline by Rubicon Biotechnology Inc, H1 2017
Prostate Cancer - Pipeline by Sanofi, H1 2017
Prostate Cancer - Pipeline by Selexel Sarl, H1 2017
Prostate Cancer - Pipeline by Senhwa Biosciences Inc, H1 2017
Prostate Cancer - Pipeline by Serometrix LLC, H1 2017
Prostate Cancer - Pipeline by Shenogen PharmaGroup Ltd, H1 2017
Prostate Cancer - Pipeline by Shire Plc, H1 2017
Prostate Cancer - Pipeline by Sierra Oncology Inc, H1 2017
Prostate Cancer - Pipeline by Sophiris Bio Inc, H1 2017
Prostate Cancer - Pipeline by Soricimed Biopharma Inc, H1 2017
Prostate Cancer - Pipeline by Sorrento Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Sotio AS, H1 2017
Prostate Cancer - Pipeline by Steba Biotech SA, H1 2017
Prostate Cancer - Pipeline by Supratek Pharma Inc, H1 2017
Prostate Cancer - Pipeline by SynDevRx Inc, H1 2017
Prostate Cancer - Pipeline by SyntheX Inc, H1 2017
Prostate Cancer - Pipeline by TaiGen Biotechnology Co Ltd, H1 2017
Prostate Cancer - Pipeline by Taiho Pharmaceutical Co Ltd, H1 2017
Prostate Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2017
Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Prostate Cancer - Pipeline by Takis Srl, H1 2017
Prostate Cancer - Pipeline by Targovax ASA, H1 2017
Prostate Cancer - Pipeline by Tarrex Biopharma Ltd, H1 2017
Prostate Cancer - Pipeline by Terpenoid Therapeutics Inc, H1 2017
Prostate Cancer - Pipeline by Tesaro Inc, H1 2017
Prostate Cancer - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017
Prostate Cancer - Pipeline by The Female Health Company, H1 2017
Prostate Cancer - Pipeline by Theravectys SA, H1 2017
Prostate Cancer - Pipeline by Threshold Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by Tolero Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
Prostate Cancer - Pipeline by TREAT U SA, H1 2017
Prostate Cancer - Pipeline by Triphase Accelerator Corp, H1 2017
Prostate Cancer - Pipeline by TVAX Biomedical Inc, H1 2017
Prostate Cancer - Pipeline by Tyme Technologies Inc, H1 2017
Prostate Cancer - Pipeline by UbiVac LLC, H1 2017
Prostate Cancer - Pipeline by Ultimovacs AS, H1 2017
Prostate Cancer - Pipeline by Vaccibody AS, H1 2017
Prostate Cancer - Pipeline by ValiRx Plc, H1 2017
Prostate Cancer - Pipeline by Vasgen Ltd, H1 2017
Prostate Cancer - Pipeline by Vault Pharma Inc, H1 2017
Prostate Cancer - Pipeline by Vaxeal Holding SA, H1 2017
Prostate Cancer - Pipeline by Vaxon Biotech, H1 2017
Prostate Cancer - Pipeline by Vicore Pharma AB, H1 2017
Prostate Cancer - Pipeline by Vicus Therapeutics LLC, H1 2017
Prostate Cancer - Pipeline by Viralytics Ltd, H1 2017
Prostate Cancer - Pipeline by ViraTherapeutics GmbH, H1 2017
Prostate Cancer - Pipeline by VLP Therapeutics LLC, H1 2017
Prostate Cancer - Pipeline by Wilex AG, H1 2017
Prostate Cancer - Pipeline by WntResearch AB, H1 2017
Prostate Cancer - Pipeline by Xencor Inc, H1 2017
Prostate Cancer - Pipeline by Yungjin Pharm Co Ltd, H1 2017
Prostate Cancer - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2017
Prostate Cancer - Dormant Projects, H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..1), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..2), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..3), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..4), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..5), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..6), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..7), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..8), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..9), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..10), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..11), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..12), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..13), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..14), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..15), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..16), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..17), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..18), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..19), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..20), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..21), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..22), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..23), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..24), H1 2017
Prostate Cancer - Dormant Projects, H1 2017 (Contd..25), H1 2017
Prostate Cancer - Discontinued Products, H1 2017
Prostate Cancer - Discontinued Products, H1 2017 (Contd..1), H1 2017
Prostate Cancer - Discontinued Products, H1 2017 (Contd..2), H1 2017
Prostate Cancer - Discontinued Products, H1 2017 (Contd..3), H1 2017
Prostate Cancer - Discontinued Products, H1 2017 (Contd..4), H1 2017
Prostate Cancer - Discontinued Products, H1 2017 (Contd..5), H1 2017

List of Figures
Number of Products under Development for Prostate Cancer, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Top 10 Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *